Paracrine Gene Therapy
Renova Therapeutics’ proprietary paracrine gene therapy treatments are based on a novel systemic approach that introduces therapeutic genes capable of directing the body’s cells to work more normally. This single-IV injection approach is a foundation for products that may bring about permanent improvements in a variety of chronic cardiovascular and metabolic diseases.
Paracrine gene therapy is a wholly novel approach developed by Dr. H. Kirk Hammond, Professor of Medicine, University of California, San Diego, a cardiologist at the Veterans Affairs San Diego Healthcare System, and co-founder of Renova Therapeutics. This approach involves sustained activity following systemic delivery of the therapeutic signaling gene to the blood serum, where it can exert beneficial effects on target organs from a distance.
Paracrine gene therapy has been shown to dramatically improve animal models of congestive heart failure, type 2 diabetes and other chronic diseases. In proof-of-concept studies, after type 2 diabetes was established in animal models, a single dose of the paracrine gene therapy normalized these animals. Animals treated with the paracrine gene therapy metabolized glucose more efficiently than the control group; the treatment was also associated with resolution of hyperinsulinemia, increases in beta cell function and insulin sensitivity, and reduced insulin resistance.
In similar protocols in which animals were dosed initially prior to being fed a high-fat diet, treated animals did not develop type 2 diabetes in their lifetime – signaling a potential for a preventative therapy.
Paracrine gene therapy is a foundation for products that bring about permanent improvements in CHF and type 2 diabetes. It also unlocks the potential for treatment of other chronic diseases, including pulmonary hypertension, non-alcoholic fatty liver disease and obesity.